

ANNUAL REPORT AND FINANCIAL STATEMENTS
MERIT MEDICAL UK LIMITED
FOR THE YEAR ENDED
31 DECEMBER 2021
COMPANY NUMBER: 3001008



MERIT MEDICAL UK LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

CONTENTS	PAGE
DIRECTORS AND OTHER INFORMATION	2
DIRECTORS' REPORT	3 - 4
DIRECTORS' RESPONSIBILITIES STATEMENT	5
INDEPENDENT AUDITOR'S REPORT	6 - 8
STATEMENT OF ACCOUNTING POLICIES	9 - 10
STATEMENT OF COMPREHENSIVE INCOME	11
BALANCE SHEET	12
STATEMENT OF CHANGES IN EQUITY	13
NOTES TO THE FINANCIAL STATEMENTS	14 - 20

MERIT MEDICAL UK LIMITED
DIRECTORS AND OTHER INFORMATION

DIRECTORS

**Fred Lampropoulos
Mark Butler
Brian Glen Lloyd**

SECRETARY

Vistra Company Secretaries Limited

REGISTERED OFFICE

**Unit 27 Suttons Business Park
Sutton Park Avenue
Earley
Reading
Berkshire
RG6 1 AZ
United Kingdom**

AUDITOR

**Deloitte Ireland LLP
Chartered Accountants and Statutory Audit Firm
Charlottes' Quay
Limerick**

BANKERS

**Bank of America
5 Canada Square
London
E14 5AQ
United Kingdom**

**HSBC
60 Queen Victoria Street
London
EC 4N
UK**

SOLICITOR

**A & L Goodbody
North Wall Quay
Dublin 1
Ireland**

COMPANY NUMBER

3001008

MERIT MEDICAL UK LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2021

The directors present their annual report and the audited financial statements of the company for the year ended 31 December 2021. This directors' report has been prepared in accordance with the provisions applicable to companies subject to the small companies' exemption.

RESULTS AND DIVIDENDS

The profit after taxation for the year amounted to £830,053 (2020: £650,833).

The directors recommend that no dividend be paid (2020: £Nil).

KEY PERFORMANCE INDICATOR

Commission income has decreased from 2020 to 2021. The company is a subsidiary of Merit Holdings Inc. As part of an overall restructuring of the operations of Merit Holdings Inc., the activity of the company changed during the 2020 financial year from a commissionaire model to a buy/sell model.

DIRECTORS

The directors, who served at all times during the year except as noted, were as follows:

Fred Lampropoulos
Mark Butler
Brian Glen Lloyd

COMPANY NUMBER

The company number is 3001008.

DIRECTORS' INTEREST IN SHARES

None of the directors who held office at 31 December 2021 had any beneficial interest in the shares of the company at 31 December 2021, or 1 January 2021.

The directors at 31 December 2021 beneficially held the following shares in the parent company, Merit Medical Systems Inc.

Beneficial interests:

	31/12/2021			01/01/2021		
	No. Ordinary Shares	No. Ordinary Options	No. PSUs	No. Ordinary Shares	No. Ordinary Options	No. PSUs
Fred Lampropoulos	1,063,835	605,570	28,365	967,916	547,487	21,215
Mark Butler	-	60,000	-	-	75,000	-
Brian Glen Lloyd	6,696	111,403	10,636	114	146,722	7,995

Certain directors have options to acquire shares in Merit Medical Systems Inc. as follows:

	1 January 2021	Adjustments	Exercised during year	Cancelled during year	Granted during year	31 December 2021	Average option price US\$
Fred Lampropoulos	547,487	-	-	-	58,083	605,570	39.74
Mark Butler	75,000	-	(25,000)	-	10,000	60,000	46.83
Brian Glen Lloyd	146,722	-	(45,000)	-	9,681	111,403	43.20

MERIT MEDICAL UK LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2021

Certain directors have PSU's as follows:

	1 January 2021	Adjustments	Released during year	Cancelled during year	Granted during year	31 December 2021	Average option price US\$
Fred Lampropoulos	21,215	-	(7,072)	-	14,222	28,365	52.56
Mark Butler	-	-	-	-	-	-	-
Brian Glen Lloyd	7,995	(40)	(2,652)	-	5,333	10,636	52.56

EVENTS AFTER THE BALANCE SHEET DATE

Details of significant events since the balance sheet date are contained in note 19 to the financial statements.

AUDITOR


Each of the persons who is a director at the date of approval of this report confirms that:


- (1) So far as the director is aware, there is no relevant audit information of which the company's auditors are unaware; and
- (2) The director has taken all the steps that he/she ought to have taken as a director in order to make him/herself aware of any relevant audit information and to establish that the company's auditor is aware of that information.

This confirmation is given and should be interpreted in accordance with the provision of s418 of the Companies Act 2006.

Deloitte Ireland LLP, Statutory Auditor, continue in office as auditor and a resolution to reappoint them will be proposed at the forthcoming Annual General Meeting.

Approved by the Board and signed on its behalf by:

DocuSigned by:

 FRED LAMPROPOULOS
 DIRECTOR

DocuSigned by:

 BRIAN GLEN LLOYD
 DIRECTOR

Date: 22 September 2022

MERIT MEDICAL UK LIMITED
DIRECTORS' RESPONSIBILITIES STATEMENT

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law) including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland". Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The directors are responsible for the maintenance and integrity of the corporate and financial information included on the company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Independent auditor's report to the members of Merit Medical UK Limited

Report on the audit of the financial statements

Opinion

In our opinion the financial statements of Merit Medical UK Limited (the 'company'):

- give a true and fair view of the state of the company's affairs as at 31 December 2021 and of its profit for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice, including Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland"; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

We have audited the financial statements which comprise:

- the statement of comprehensive income;
- the balance sheet;
- the statement of changes in equity;
- the statement of accounting policies; and
- the related notes 1 to 19.

The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (United Kingdom Generally Accepted Accounting Practice).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report.

We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the Financial Reporting Council's (the 'FRC's') Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Our evaluation of the directors' assessment of the company's ability to continue to adopt the going concern basis of accounting included:

- The profit generated in the year, net current asset position and net asset position at 31 December 2021;
- The financial performance of the company since the year end date;
- The future projected cash flows from projects for a minimum period of 12 months from the date of approval of the financial statements.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Continued on next page/

/Continued from the previous page

Independent auditor's report to the members of Merit Medical UK Limited

Report on the audit of the financial statements

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the FRC's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Extent to which the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

We considered the nature of the company's industry and its control environment, and reviewed the company's documentation of their policies and procedures relating to fraud and compliance with laws and regulations. We also enquired of management about their own identification and assessment of the risks of irregularities.

We obtained an understanding of the legal and regulatory frameworks that the company operates in, and identified the key laws and regulations that:

- had a direct effect on the determination of material amounts and disclosures in the financial statements. These included the UK Companies Act 2006 and Tax legislation; and
- do not have a direct effect on the financial statements but compliance with which may be fundamental to the company's ability to operate or to avoid a material penalty. These included Money Laundering Regulations, Health and Safety Legislation and the Data Protection Act.

We discussed among the audit engagement team regarding the opportunities and incentives that may exist within the organisation for fraud and how and where fraud might occur in the financial statements.

Continued on next page/

/Continued from the previous page

Independent auditor's report to the members of Merit Medical UK Limited

Report on the audit of the financial statements

In common with all audits under ISAs (UK), we are also required to perform specific procedures to respond to the risk of management override. In addressing the risk of fraud through management override of controls, we tested the appropriateness of journal entries and other adjustments; assessed whether the judgements made in making accounting estimates are indicative of a potential bias; and evaluated the business rationale of any significant transactions that are unusual or outside the normal course of business.

In addition to the above, our procedures to respond to the risks identified included the following:

- reviewing financial statement disclosures by testing to supporting documentation to assess compliance with provisions of relevant laws and regulations described as having a direct effect on the financial statements;
- performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;
- enquiring of management legal counsel concerning actual and potential litigation and claims, and instances of non-compliance with laws and regulations; and
- reading minutes of meetings of those charged with governance

Report on other legal and regulatory requirements

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the directors' report has been prepared in accordance with applicable legal requirements.

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified any material misstatements in [the strategic report or] the directors' report.

Matters on which we are required to report by exception

Under the Companies Act 2006 we are required to report in respect of the following matters if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

We have nothing to report in respect of these matters.

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.



Cathal Treacy FCA (Senior statutory auditor)
For and on behalf of Deloitte LLP
Statutory Auditor
Deloitte and Touche House
Charlottes Quay
Limerick

Date: 23 September 2022

MERIT MEDICAL UK LIMITED
STATEMENT OF ACCOUNTING POLICIES

The significant accounting policies adopted by the company are as follows:

GENERAL INFORMATION AND BASIS OF ACCOUNTING

Merit Medical UK Limited is a company incorporated in the United Kingdom under the Companies Act 2006. The address of the registered office is given on page 2. The nature of the company's operations and its principal activities are set out in the directors' report on pages 3 to 4.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with the Companies Act 2006 and Financial Reporting Standard 102 (FRS 102) issued by the Financial Reporting Council.

The functional currency of Merit Medical UK Limited is considered to be sterling because that is the currency of the primary economic environment in which the company operates.

These financial statements are separate financial statements.

Merit Medical UK Limited meets the definition of a qualifying entity under FRS 102 and has therefore taken advantage of the disclosure exemptions available to it in respect of its separate financial statements. Merit Medical UK Limited is consolidated in the financial statements of its parent Merit Medical Systems Inc. Exemptions have been taken in these separate company financial statements in relation to the presentation of a statement and remuneration of key management personnel.

Going Concern

The Board of Directors has considered, as at the date of its approval of these financial statements, the possible impact of external events on the operations of the Company and the Company's ability to continue as a going concern. In particular, the Board has reviewed the level of possible risks associated with customer credit worthiness, customer demand, order pipeline, supplier and procurement continuity, personnel availability, and the group's ability to meet its obligations in the event of reduced cash. The Board believes that the Company has sufficient resources to continue as a going concern for the foreseeable future.

Turnover

Turnover is stated net of VAT and trade discounts and is recognised when the significant risks and rewards are considered to have been transferred to the buyer. Turnover from the sale of goods is recognised when the goods are physically delivered to the customer.

Tangible assets

Tangible fixed assets are stated at cost, net of depreciation and any allowance for impairment. Depreciation is provided on all tangible fixed assets at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line basis over its expected useful life, as follows:

Office Equipment	33½% per annum
Computer Software	20% per annum
Furniture and Fixtures	14.28% per annum
Furniture and Fixtures- Other	11.11% per annum

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

MERIT MEDICAL UK LIMITED
STATEMENT OF ACCOUNTING POLICIES

Foreign currencies

Transactions denominated in foreign currencies relating to revenues, costs, and non-monetary assets are translated into sterling at the monthly rate of exchange.

Monetary assets and liabilities denominated in a foreign currency are translated into sterling at the rate of exchange ruling at the balance sheet date.

All profits and losses arising on exchange are reflected in the statement of comprehensive income.

Taxation

Current tax, including UK corporation tax and foreign tax, is provided at amounts expected to be paid (or recovered) using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events that result in an obligation to pay more tax in the future or a right to pay less tax in the future have occurred at the balance sheet date. *Timing differences are differences between the company's taxable profits and its results as stated in the financial statements that arise from the inclusion of gains and losses in tax assessments in years different from those in which they are recognised in the financial statements.*

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that, on the basis of all available evidence, it can be regarded as more likely than not that there will be suitable taxable profits from which the future reversal of the underlying timing differences can be deducted.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date that are expected to apply to the reversal of the timing difference. Deferred tax relating to property, plant and equipment measured using the revaluation model and investment property is measured using the tax rates and allowances that apply to sale of the asset.

Where items recognised in other comprehensive income or equity are chargeable to or deductible for tax purposes, the resulting current or deferred tax expense or income is presented in the same component of comprehensive income or equity as the transaction or other event that resulted in the tax expense or income.

Current tax assets and liabilities are offset only when there is a legally enforceable right to set off the amounts and the company intends either to settle on a net basis or to realise the asset and settle the liability simultaneously.

Deferred tax assets and liabilities are offset only if: a) the company has a legally enforceable right to set off current tax assets against current tax liabilities; and b) the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same taxation authority on the company and the company intends either to settle current tax liabilities and assets on a net basis, or to realise the assets and settle the liabilities simultaneously, in each future year in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.

Retirement benefit obligations

For defined benefit schemes the amounts charged to operating profit are the costs arising from employee services rendered during the year and the cost of plan introductions, benefit changes, settlements and curtailments. They are included as part of staff costs. The net interest cost on the net defined benefit liability is charged to statement of comprehensive income and included within finance costs. Remeasurement comprising actuarial gains and losses and the return on scheme assets (excluding amounts included in net interest on the net defined benefit liability) are recognised immediately in other comprehensive income.

For defined contribution schemes the amounts charged to the statement of comprehensive income in respect of pension costs and other post-retirement benefits are the contributions payable in the year. Differences between contributions payable in the year and contributions actually paid are shown as either accruals or prepayments in the balance sheet.

Other long-term employee benefits are measured at the present value of the benefit obligation at the reporting date.

Leases

All operating lease rentals are charged to the statement of comprehensive income on a straight line basis.

MERIT MEDICAL UK LIMITED
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2021


	Note	2021 £	2020 £
TURNOVER	2	18,558,129	15,841,908
Cost of Sales		(13,420,400)	(11,446,269)
OPERATING PROFIT		5,137,729	4,395,639
Other operating expenses	3	(4,191,527)	(3,784,689)
Other income	6	24,585	120,155
PROFIT ON ORDINARY ACTIVITIES BEFORE TAXATION	7	970,787	731,105
Taxation	8	(140,734)	(80,272)
PROFIT FOR THE YEAR ATTRIBUTABLE TO THE EQUITY SHAREHOLDERS OF THE COMPANY		830,053	650,833
Other comprehensive income		-	-
TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO THE EQUITY SHAREHOLDERS OF THE COMPANY		830,053	650,833


All recognised gains and losses for both the current year and the previous year are included in the statement of comprehensive income. All of the above derive from continuing operations.

MERIT MEDICAL UK LIMITED
BALANCE SHEET AS AT 31 DECEMBER 2021

	Note	2021 £	2020 £
FIXED ASSETS			
Tangible assets	9	844,846	963,118
Financial assets	10	15,829	15,829
		860,675	978,947
CURRENT ASSETS			
Stock	11	2,462,336	1,732,842
Debtors	12	5,405,714	5,538,560
Cash at bank and in hand		1,231,010	1,212,645
Deferred Tax Asset	14	47,469	22,874
		9,146,529	8,506,921
CREDITORS (Amounts falling due within one year)	13	(5,687,689)	(5,996,406)
NET CURRENT ASSETS		3,458,840	2,510,515
TOTAL ASSETS LESS CURRENT LIABILITIES		4,319,515	3,489,462
PROVISION FOR LIABILITIES AND CHARGES		-	-
NET ASSETS		4,319,515	3,489,462
CALLED UP SHARE CAPITAL AND RESERVES			
Called up share capital	15	100	100
Profit and loss account	15	4,319,415	3,489,362
SHAREHOLDERS' FUNDS		4,319,515	3,489,462

The financial statements of Merit Medical UK Limited, 3001008, were approved by the board of directors on 22 September 2022 and signed on its behalf by:

DocuSigned by:

 FRED LAMPROPOULOS
 DIRECTOR

DocuSigned by:

 BRIAN GLEN LLOYD
 DIRECTOR

MERIT MEDICAL UK LIMITED**STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2021**

	Called up share capital £	Profit and loss account £	Total £
AT 1 JANUARY 2021	100	3,489,362	3,489,462
Total comprehensive income	-	830,053	830,053
	<hr/>	<hr/>	<hr/>
AT 31 DECEMBER 2021	100	4,319,415	4,319,515
	<hr/>	<hr/>	<hr/>
In respect of the prior year:			
	Called up share capital £	Profit and loss account £	Total £
AT 1 JANUARY 2020	100	2,838,529	2,838,629
Total comprehensive income	-	650,833	650,833
	<hr/>	<hr/>	<hr/>
AT 31 DECEMBER 2020	100	3,489,362	3,489,462
	<hr/>	<hr/>	<hr/>

MERIT MEDICAL UK LIMITED**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021****1. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY**

In the application of the company's accounting policies, which are described in the Statement of Accounting Policies, the director is required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the year in which the estimate is revised if the revision affects only that year or in the year of the revision and future years if the revision affects both current and future years.

Critical judgements in applying the company's accounting policies

There were no critical judgements made by the directors during the year in the process of applying the company's accounting policies.

2. TURNOVER

	2021 £	2020 £
An analysis of the company's turnover by geographical market is set out below:		
United Kingdom	18,558,129	15,841,908
	<u> </u>	<u> </u>
An analysis of the company's turnover is as follows:		
Commission income	1,151,813	1,326,960
Product Sales	17,406,316	14,514,948
	<u> </u>	<u> </u>
	18,558,129	15,841,908
	<u> </u>	<u> </u>

3. OTHER OPERATING EXPENSES

	2021 £	2020 £
Distribution costs	3,404,080	2,802,263
Administrative expenses	888,357	892,960
Foreign exchange (gain)/loss	(100,910)	89,466
	<u> </u>	<u> </u>
	4,191,527	3,784,689
	<u> </u>	<u> </u>

4. DIRECTORS' REMUNERATION

The remuneration paid to the directors of Merit Medical UK Limited was:

	2021 £	2020 £
Fees	-	-
Other remuneration (including pension contributions and benefits in kind)	-	-
	<u> </u>	<u> </u>
	-	-
	<u> </u>	<u> </u>

MERIT MEDICAL UK LIMITED**NOTES TO THE FINANCIAL STATEMENTS- CONTINUED
FOR THE YEAR ENDED 31 DECEMBER 2021****5. EMPLOYEES AND REMUNERATION**

The average monthly number of persons employed during the year was:

	2021 Number	2020 Number
Marketing and sales	33	35
	2021 £	2020 £
Wages and salaries	2,582,168	2,338,364
National insurance	473,643	321,549
Retirement benefit obligations (Note 17)	80,170	95,606
Severance expense	477,427	255,948
	3,613,408	3,011,467

6. OTHER INCOME

	2021 £	2020 £
Intercompany interest receivable	24,585	14,654
Government Wage Subsidy Scheme	-	105,501
	24,585	120,155

**7. PROFIT ON ORDINARY ACTIVITIES
BEFORE TAXATION**

	2021 £	2020 £
Profit on ordinary activities before taxation is stated after charging/(crediting):		
Depreciation of tangible assets	179,766	177,947
Operating lease charges	110,129	139,386
Foreign exchange (gain)/ loss	(100,910)	89,466

MERIT MEDICAL UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS- CONTINUED
FOR THE YEAR ENDED 31 DECEMBER 2021

8. TAXATION	2021	2020
	£	£
Taxation charge for the year		
United Kingdom current year corporation tax	227,315	198,296
Overprovision in respect of prior year	(61,986)	(60,249)
Current tax charge for the year	165,329	138,047
Deferred tax charge (Note 14)	(24,595)	(57,775)
	140,734	80,272
	2021	2020
	£	£
Factors affecting tax charge for the year		
Profit on ordinary activities before taxation	970,787	731,005
Profit on ordinary activities multiplied by the standard rate of taxation of 19% (2020: 19%)	184,450	138,891
Effects of:		
Items not deductible for tax purposes	8,710	27,894
Depreciation in excess of capital allowances	34,155	31,511
Current taxation charge for the year	227,315	198,296

MERIT MEDICAL UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS - CONTINUED
FOR THE YEAR ENDED 31 DECEMBER 2021**9. TANGIBLE ASSETS**

	Office Equipment	Computer Software	Furniture and Fixtures	Furniture and Fixtures- Other	Total
	£	£	£	£	£
Cost:					
At 1 January 2021	68,712	204,484	589,533	325,061	1,187,790
Additions	-	23,062	-	41,052	64,114
Disposals	-	(25,637)	-	-	(25,637)
At 31 December 2021	68,712	201,909	589,533	366,113	1,226,267
Accumulated depreciation:					
At 1 January 2021	55,706	35,895	93,942	39,129	224,672
Charge for the period	10,126	40,285	93,237	36,118	179,766
Disposals	-	(23,017)	-	-	(23,017)
At 31 December 2021	65,832	53,163	187,179	75,247	381,421
Net book value:					
At 31 December 2021	2,880	148,746	402,354	290,866	844,846
At 31 December 2020	13,006	168,589	495,555	285,932	963,118

MERIT MEDICAL UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS - CONTINUED
FOR THE YEAR ENDED 31 DECEMBER 2021

10. FINANCIAL ASSETS	2021 £
	Total
Cost:	£
Investment in subsidiary at cost (unlisted) at 1 January 2021	15,829
Additions in the current year	-
At 31 December 2021	15,829

Subsidiary Undertaking (Wholly Owned)

Name	Registered Office	Nature of Business
Merit Medical Australia Ltd	Baker McKenzie L19 181 William Street Melbourne VIC 3000 Australia	Sale and Distribution of Medical Devices
Merit Medical Spain Ltd	Doctor Fleming 31 -28036 Madrid Spain	Sale and Distribution of Medical Devices
Merit Medical Colombia SAS	Carrera 9 #115-06 Tierra Firme Piso 17 Bogota Colombia	Sales and Distribution of Medical Devices

The directors are satisfied that the carrying values of the investments do not exceed the recoverable amount.

Consolidated financial statements have not been prepared by the company as the company's ultimate parent company, Merit Medical Systems Inc., prepares group financial statements which include the results of the company and its subsidiaries made up to 31 December 2021.

11. STOCK	2021 £	2020 £
Goods in transit	103,204	139,359
Finished goods	2,359,132	1,593,483
	2,462,336	1,732,842

The replacement cost of stocks does not differ significantly from the amounts stated above.

MERIT MEDICAL UK LIMITED**NOTES TO THE FINANCIAL STATEMENTS - CONTINUED
FOR THE YEAR ENDED 31 DECEMBER 2021**

12. DEBTORS	2021	2020
	£	£
Amounts falling due within one year:		
Trade Debtors	2,557,778	2,782,987
Amount due from group company	2,801,901	2,623,858
Other debtors	-	4,874
Prepayments	46,035	126,841
	5,405,714	5,538,560

13. CREDITORS (Amounts falling due within one year)	2021	2020
	£	£
Trade creditors	156,488	51,476
Accruals	352,670	178,655
Amounts due to group company	4,912,689	5,310,794
Corporation tax payable	27,933	49,454
Social security payable	96,071	66,638
VAT Payable	141,838	339,389
	5,687,689	5,996,406

14. DEFERRED TAX	2021	2020
	£	£
Deferred tax		
Accelerated capital allowances	47,469	22,874

15. CALLED UP SHARE CAPITAL AND RESERVES	2021	2020
	£	£
Allotted, called-up and fully paid:		
100 Ordinary shares of £1 each	100	100

The company's other reserves are as follows:

The profit and loss reserve represents cumulative profits or losses, net of dividends paid and other adjustments.

16. OPERATING LEASES

Total future minimum lease payments under non-cancellable operating leases as follows:

	2021	2020
	£	£
Payable:		
- Within one year	311,201	307,492
- Between two to five years	864,234	616,457
- More than five years	518,203	706,640
	1,693,638	1,630,589

MERIT MEDICAL UK LIMITED

**NOTES TO THE FINANCIAL STATEMENTS - CONTINUED
FOR THE YEAR ENDED 31 DECEMBER 2021**

17. RETIREMENT BENEFIT OBLIGATIONS

The company operates a defined contribution scheme for employees. The assets of the scheme are held separately from those of the company. The total pension cost to the company in the year was £80,170 (2020: £95,606). The amount owing at 31 December 2021 was £12,106 (2020: £14,188).

18. PARENT COMPANY AND RELATED PARTY TRANSACTIONS

The company is a subsidiary of Merit Holdings Inc., a company incorporated in the U.S.A. The company's ultimate parent company is Merit Medical Systems Inc., a company incorporated in the U.S.A.

A significant proportion of the company's income arises from the sale of group products. Certain expenses and services are shared with a fellow group company and apportioned as deemed appropriate by management.

The company has availed of the exemption provisions of Financial Reporting Standard 102 (S.33) on Related Party Transactions on the grounds of being a wholly owned subsidiary. Copies of the consolidated financial statements of the parent company are available from 1600 West Merit Parkway, South Jordan, Utah, U.S.A.

19. EVENTS AFTER THE BALANCE SHEET DATE

There were no material post balance sheet events.